title: Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda.
abstract: Porphyria cutanea tarda is a liver disease characterized by elevated hepatic iron and excessive production of uroporphyrin (URO). Phlebotomy is an effective treatment that probably acts by reducing hepatic iron. Here we used Hfe(-/-) mice to compare the effects on hepatic URO accumulation of two different methods of hepatic iron depletion: iron chelation using deferiprone (L1) versus iron-deficient diets. Hfe(-/-) mice in a 129S6/SvEvTac background were fed 5-aminolevulinic acid (ALA), which results in hepatic URO accumulation, and increasing doses of L1 in the drinking water. Hepatic URO accumulation was completely prevented at low L1 doses, which partially depleted hepatic nonheme iron. By histological assessment, the decrease in hepatic URO accumulation was associated with greater depletion of iron from hepatocytes than from Kupffer cells. The L1 treatment had no effect on levels of hepatic cytochrome P4501A2 (CYP1A2). L1 also effectively decreased hepatic URO accumulation in C57BL/6 Hfe(-/-) mice treated with ALA and a CYP1A2 inducer. ALA-treated mice maintained on defined iron-deficient diets, rather than chow diets, did not develop uroporphyria, even when the animals were iron-supplemented either directly in the diet or by iron dextran injection.
  
  
  CONCLUSIONS
  The results suggest that dietary factors other than iron are involved in the development of uroporphyria and that a modest depletion of hepatocyte iron by L1 is sufficient to prevent URO accumulation.
authors.affiliation: Veterans Affairs Medical Center, White River Junction, VT 05009, USA.
authors.forename: Nadia
authors.initials: N
authors.lastname: Gorman
authors.forename: Adrian
authors.initials: A
authors.lastname: Zaharia
authors.forename: Heidi S
authors.initials: HS
authors.lastname: Trask
authors.forename: Juliana G
authors.initials: JG
authors.lastname: Szakacs
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Jacobs
authors.forename: Judith M
authors.initials: JM
authors.lastname: Jacobs
authors.forename: Dominic
authors.initials: D
authors.lastname: Balestra
authors.forename: Jacqueline F
authors.initials: JF
authors.lastname: Sinclair
authors.forename: Peter R
authors.initials: PR
authors.lastname: Sinclair
mesh_terms: D000818:Animals; D000077543:Deferiprone; D004195:Disease Models, Animal; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D000090463:Iron Deficiencies; D008099:Liver / Q000737:chemistry; D008297:Male; D051379:Mice; D017119:Porphyria Cutanea Tarda / Q000178:diet therapy* / Q000188:drug therapy*; D011728:Pyridones / Q000627:therapeutic use*; D014578:Uroporphyrins / Q000032:analysis
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D014578:Uroporphyrins; D000077543:Deferiprone